Literature DB >> 12810865

Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice.

M J Wallace1, D W Smith2, A K Broom1, J S Mackenzie3, R A Hall3, G R Shellam1, P C McMinn4,1.   

Abstract

Enhancement of flavivirus infection in vitro in the presence of subneutralizing concentrations of homologous or heterologous antiserum has been well described. However, the importance of this phenomenon in the enhancement of flavivirus infection in vivo has not been established. In order to study antibody-mediated enhancement of flavivirus infection in vivo, we investigated the effect of passive immunization of mice with Japanese encephalitis virus (JE) antiserum on the outcome of infection with Murray Valley encephalitis virus (MVE). We show that prior treatment of mice with subneutralizing concentrations of heterologous JE antiserum resulted in an increase in viraemia titres and in mortality following challenge with wild-type MVE. Our findings support the hypothesis that subneutralizing concentrations of antibody may enhance flavivirus infection and virulence in vivo. These findings are of potential importance for the design of JE vaccination programs in geographic areas in which MVE co-circulates. Should subneutralizing concentrations of antibody remain in the population following JE vaccination, it is possible that enhanced disease may be observed during MVE epidemics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810865     DOI: 10.1099/vir.0.18980-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  19 in total

Review 1.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

2.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

Review 3.  Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Expert Rev Mol Med       Date:  2008-05-12       Impact factor: 5.600

4.  Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?

Authors:  Evgeny Shmelkov; Arthur Nadas; Timothy Cardozo
Journal:  Hum Vaccin Immunother       Date:  2014-11-21       Impact factor: 3.452

5.  Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology.

Authors:  Kerrie Vaughan; Jason Greenbaum; Martin Blythe; Bjoern Peters; Alessandro Sette
Journal:  Viral Immunol       Date:  2010-06       Impact factor: 2.257

6.  An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.

Authors:  Mario Lobigs; Megan Pavy; Roy A Hall; Päivi Lobigs; Peter Cooper; Tomoyoshi Komiya; Hiroko Toriniwa; Nikolai Petrovsky
Journal:  J Gen Virol       Date:  2010-02-03       Impact factor: 3.891

7.  Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.

Authors:  Scott J Balsitis; Katherine L Williams; Ruben Lachica; Diana Flores; Jennifer L Kyle; Erin Mehlhop; Syd Johnson; Michael S Diamond; P Robert Beatty; Eva Harris
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

8.  Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus.

Authors:  Mario Lobigs; Maximilian Larena; Mohammed Alsharifi; Eva Lee; Megan Pavy
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

Review 9.  Dengue virus pathogenesis: an integrated view.

Authors:  Byron E E Martina; Penelope Koraka; Albert D M E Osterhaus
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

10.  Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens.

Authors:  Wayne D Crill; Holly R Hughes; Mark J Delorey; Gwong-Jen J Chang
Journal:  PLoS One       Date:  2009-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.